Verona Pharma plc
VRNA
Rang in Aktien
#2227
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Aktienkurs
$106.91
Zuletzt synchronisiert: 2025-10-07
Marktkapitalisierung
$9.09B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
GB
Handel Verona Pharma plc (VRNA)
Kategorie
Healthcare
P/S-Verhältnis für Verona Pharma plc (VRNA)
P/S-Verhältnis zum October 2026 TTM: 2.15K
Laut den neuesten Finanzberichten und dem Aktienkurs von Verona Pharma plc beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 2.15K. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 0.00.
P/S-Verlauf für Verona Pharma plc von 2005 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 2.15K | 1,849.31% |
| 2024 | 110.41 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | 3.77K | 37,827.00% |
| 2021 | 9.94 | 0.00% |
| 2020 | 0.00 | -100.00% |
| 2019 | 24.28K | -32.01% |
| 2018 | 35.71K | 65,523.71% |
| 2017 | 54.42 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.02 | -99.53% |
US
|
|
| 40.55 | -98.12% |
US
|
|
| 3.96 | -99.82% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.53% |
NL
|
